Summit Therapeutics plc

In the competitive PD-L1xVEGF bispecific antibody development space, BioNTech is looking to be an early leader with partner Bristol Myers Squibb. BioNTech brought Bristol on as a partner for BNT327 in

Chinese biotechs are racing to push back the frontiers of combination therapies for antibody-drug conjugates (ADCs), progressing multiple assets into mid-stage clinical development. Beyond the validat

There were fireworks ahead of the 4th of July festivities over the pharma sector as analysts weighed in on the rumors that a multi-billion dollar deal is in the offing between AstraZeneca and Summit T

Summit Therapeutics and Akeso delivered mixed results from the first multi-regional Phase III study of ivonescimab, the companies’ PD-1/VEGF-targeting immunotherapy, in non-small cell lung cancer (NSC